Company intelligence / Profile preview

Shanghai MediPharm Biotech

Shanghai, Shanghai Shi, China

Ownership: Private
Employees: ~53
Development stage: Other

Overview

Shanghai MediPharm Biotech commercialized the first radioimmunotherapy for solid tumors (Vivatuxin®, a chimeric tumor necrosis therapy) approved for lung cancer in China in 2007, with ongoing Phase III and preclinical trials in multiple solid tumor indications. Clinical supply agreements cover over 100 Chinese hospitals, with exclusive technology licenses from USC; company operates GMP manufacturing plant capable of producing 100,000 doses per year.

Therapeutic areas: Oncology
Modalities: Radiolabeled antibodyTherapeutic radiopharmaceuticalsAntibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

Ministry of Health of China (clinical supply/marketing)University of Southern California Cancer Therapeutic Lab (exclusive technology license)

Beyond the preview

Go deeper on Shanghai MediPharm Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai MediPharm Biotech.

Explore the full profile